niacinamide has been researched along with Colitis Gravis in 7 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The primary outcome was peficitinib dose-response at Week 8, with response assessed using Mayo score change from baseline." | 2.87 | Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study. ( Bertelsen, K; Feagan, BG; Johanns, J; Lichtenstein, GR; Marano, C; O'Brien, CD; Panes, J; Sandborn, WJ; Sands, BE; Strauss, R; Szapary, P; Vermeire, S; Yang, Z; Zhang, H, 2018) |
| "SRT1720 treatment increased the protein levels of occludin and ZO-1 and inhibited Caco-2 apoptosis, whereas NAM administration caused the opposite effects." | 1.51 | Sirtuin 1 alleviates endoplasmic reticulum stress-mediated apoptosis of intestinal epithelial cells in ulcerative colitis. ( Ding, CY; Gu, ML; Ji, F; Pan, HH; Ren, MT; Yu, MS; Zhou, XX, 2019) |
| "Without known mechanisms of action, Crohn's disease is exacerbated, and ulcerative colitis is improved, by the use of tobacco." | 1.37 | Growth of M. avium subspecies paratuberculosis in culture is enhanced by nicotinic acid, nicotinamide, and α and β nicotinamide adenine dinucleotide. ( Brown, ST; Greenstein, RJ; Su, L, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, JW | 1 |
| Kim, SY | 1 |
| Ren, MT | 1 |
| Gu, ML | 1 |
| Zhou, XX | 1 |
| Yu, MS | 1 |
| Pan, HH | 1 |
| Ji, F | 1 |
| Ding, CY | 1 |
| Ferrante, M | 1 |
| Sabino, J | 1 |
| Sands, BE | 1 |
| Sandborn, WJ | 1 |
| Feagan, BG | 1 |
| Lichtenstein, GR | 1 |
| Zhang, H | 1 |
| Strauss, R | 1 |
| Szapary, P | 1 |
| Johanns, J | 1 |
| Panes, J | 1 |
| Vermeire, S | 1 |
| O'Brien, CD | 1 |
| Yang, Z | 1 |
| Bertelsen, K | 1 |
| Marano, C | 1 |
| Biancheri, P | 1 |
| Foster, MR | 1 |
| Fyfe, MC | 1 |
| MacDonald, TT | 1 |
| Sirohi, S | 1 |
| Solanke, Y | 1 |
| Wood, E | 1 |
| Rowley, A | 1 |
| Webber, S | 1 |
| Walshe, CA | 1 |
| Greenstein, RJ | 1 |
| Su, L | 1 |
| Brown, ST | 1 |
| Jarrett, P | 1 |
| Duffill, M | 1 |
| Oakley, A | 1 |
| Smith, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events[NCT05313620] | Phase 4 | 30 participants (Anticipated) | Interventional | 2022-04-01 | Recruiting | ||
| A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-response Study Evaluating the Efficacy and Safety of JNJ-54781532 in Subjects With Moderately to Severely Active Ulcerative Colitis[NCT01959282] | Phase 2 | 219 participants (Actual) | Interventional | 2013-11-15 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for niacinamide and Colitis Gravis
| Article | Year |
|---|---|
The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment.
Topics: Adamantane; Colitis; Colitis, Ulcerative; Crohn Disease; Heterocyclic Compounds, 3-Ring; Humans; Inf | 2021 |
Efficacy of JAK inhibitors in Ulcerative Colitis.
Topics: Adamantane; Colitis, Ulcerative; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase Inhibitors; Ni | 2020 |
1 trial available for niacinamide and Colitis Gravis
| Article | Year |
|---|---|
Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study.
Topics: Adamantane; Administration, Oral; Adult; Biomarkers; C-Reactive Protein; Colitis, Ulcerative; Dose-R | 2018 |
Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study.
Topics: Adamantane; Administration, Oral; Adult; Biomarkers; C-Reactive Protein; Colitis, Ulcerative; Dose-R | 2018 |
Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study.
Topics: Adamantane; Administration, Oral; Adult; Biomarkers; C-Reactive Protein; Colitis, Ulcerative; Dose-R | 2018 |
Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study.
Topics: Adamantane; Administration, Oral; Adult; Biomarkers; C-Reactive Protein; Colitis, Ulcerative; Dose-R | 2018 |
4 other studies available for niacinamide and Colitis Gravis
| Article | Year |
|---|---|
Sirtuin 1 alleviates endoplasmic reticulum stress-mediated apoptosis of intestinal epithelial cells in ulcerative colitis.
Topics: Animals; Apoptosis; Caco-2 Cells; Caspase 12; Coculture Techniques; Colitis, Ulcerative; Dextran Sul | 2019 |
Effect of Narrow Spectrum Versus Selective Kinase Inhibitors on the Intestinal Proinflammatory Immune Response in Ulcerative Colitis.
Topics: Benzamides; Biopsy; Colitis, Ulcerative; Cytokines; Dasatinib; HT29 Cells; Humans; Interleukin-8; Le | 2016 |
Growth of M. avium subspecies paratuberculosis in culture is enhanced by nicotinic acid, nicotinamide, and α and β nicotinamide adenine dinucleotide.
Topics: Colitis, Ulcerative; Crohn Disease; Culture Media; Humans; Mycobacterium avium subsp. paratuberculos | 2011 |
Pellagra, azathioprine and inflammatory bowel disease.
Topics: Adolescent; Adult; Azathioprine; Colitis, Ulcerative; Female; Humans; Immunosuppressive Agents; Niac | 1997 |